title: Evaluation of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin in the Era of Value-Based Medicine.
abstract: Peritoneal spread from colorectal cancer is second only to the liver as a site for metastasis. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is a well-established treatment option for patients with peritoneal carcinomatosis (PC) of colorectal origin. However, due to concerns regarding both its clinical benefit and high cost, its universal adoption as the standard of care for patients with limited peritoneal dissemination has been slow. The purpose of this review was to clarify the clinical utility and cost effectiveness of CRS-HIPEC in the treatment of colorectal PC using the framework of value-based medicine, which attempts to combine both benefit and cost into a single quantifiable metric. Our comprehensive review of the clinical outcomes and cost effectiveness of CRS-HIPEC demonstrate that it is a highly valuable oncologic therapy and a good use of healthcare resources.
authors.affiliation: Division of General Surgery, Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC, Canada.
authors.forename: Tsafrir
authors.initials: T
authors.lastname: Vanounou
authors.affiliation: Division of General Surgery, Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC, Canada. richard.garfinkle@mail.mcgill.ca.
authors.forename: Richard
authors.initials: R
authors.lastname: Garfinkle
mesh_terms: D015179:Colorectal Neoplasms / Q000628:therapy*; D003131:Combined Modality Therapy; D065426:Cytoreduction Surgical Procedures; D019317:Evidence-Based Medicine; D006801:Humans; D006979:Hyperthermia, Induced; D010534:Peritoneal Neoplasms / Q000628:therapy*; D011379:Prognosis